Clinical programs supported by close of oversubscribed Series B Financing

由超额认购B系列融资关闭支持的临床项目

MILWAUKEE, Dec. 7, 2023 /PRNewswire/ -- Rivermark Medical, a company dedicated to developing a novel therapeutic device for benign prostatic hyperplasia (BPH), announced today the full enrollment of its RAPID-II clinical trial, a multi-center OUS clinical trial with sites in Australia, New Zealand, and Mexico.

密尔沃基，2023年12月7日/PRNewswire/--致力于开发一种新型良性前列腺增生（BPH）治疗设备的Rivermark Medical公司今天宣布，其RAPID-II临床试验正式注册，这是一项多中心OUS临床试验，在澳大利亚，新西兰和墨西哥进行。

The trial is funded by the company's oversubscribed Series B financing which closed earlier this year and was led by Anduril Investors LLC, a physician-founded investor group, with participation from existing investors View Ventures and Cadence Healthcare Ventures..

该试验由该公司超额认购的B系列融资提供资金，该融资于今年早些时候结束，由医生创立的投资集团安杜里投资有限责任公司（Anduril Investors LLC）牵头，现有投资者View Ventures和Cadence Healthcare Ventures参与。。

'We are excited by the efficient enrollment of our RAPID-II clinical trial. This trial enables us to capture robust real-world evidence, which will demonstrate the efficacy of our technology for patients afflicted with BPH,' stated Adam Kadlec, M.D., President and CEO of Rivermark Medical. 'All procedures were performed in the outpatient setting, utilizing a variety of flexible cystoscopes, and all patients were discharged without a post-operative catheter.

“我们对RAPID-II临床试验的有效注册感到兴奋。Rivermark Medical总裁兼首席执行官、医学博士亚当·卡德拉克（AdamKadlec）表示，这项试验使我们能够捕捉到强有力的现实证据，这将证明我们的技术对患有BPH的患者的疗效所有手术均在门诊进行，使用各种柔性膀胱镜，所有患者均在无术后导管的情况下出院。

We are thrilled with these early observations as they solidify FloStent's unique position amongst therapeutic devices for BPH.'.

我们对这些早期观察结果感到兴奋，因为它们巩固了FloStent在BPH治疗设备中的独特地位。”。

BPH is a non-cancerous condition caused by an enlarged prostate, impacting the quality of life in approximately 1 in 3 men over the age of 50. It can lead to uncomfortable symptoms such as frequent urination, difficulty urinating, and urinary tract infections (UTIs). Existing therapies may result in persistent symptoms, diminished sexual function, increased risk of infection, and a challenging recovery process for patients.

BPH是一种由前列腺增大引起的非癌性疾病，影响了大约三分之一的50岁以上男性的生活质量。它会导致不舒服的症状，如尿频、排尿困难和尿路感染（UTI）。现有疗法可能会导致持续的症状，性功能减退，感染风险增加，以及患者具有挑战性的恢复过程。

Rivermark's FloStent System is a uniquely engineered nitinol stent that gently holds the prostatic urethra open to restore normal urinary flow while preserving sexual function. The device is designed for rapid patient relief with minimal discomfort, can be deployed using any flexible cystoscope during an outpatient visit, and offers fewer complications and minimal recovery time..

Rivermark的FloStent系统是一种独特的工程镍钛合金支架，可以轻轻地保持前列腺尿道的开放，以恢复正常的尿流，同时保持性功能。该设备旨在快速缓解患者的不适感，可以在门诊就诊期间使用任何柔性膀胱镜进行部署，并发症少，恢复时间短。。

'Rivermark is revolutionizing the BPH treatment paradigm with a device that offers therapeutic intervention at the time of diagnosis,' stated Dr. Matt Ercolani, co-founder and managing partner of Anduril Investors LLC, and key opinion leader for several BPH treatment options currently on the market.

“Rivermark正在通过一种在诊断时提供治疗干预的设备彻底改变BPH治疗模式，”Anduril Investors LLC的联合创始人和管理合伙人马特·埃科拉尼（Matt Ercolani）博士表示，他是目前市场上几种BPH治疗方案的主要意见领袖。

'As an investor and clinician, I believe the technology's ability to provide immediate relief for patients while seamlessly integrating into routine urological visits will be game-changing for the treatment of BPH.'.

“作为一名投资者和临床医生，我相信该技术能够为患者提供即时缓解，同时无缝整合到常规泌尿科就诊中，这将改变BPH治疗的游戏规则。”。

About Rivermark Medical‍Rivermark Medical was founded by a practicing urologist to develop the preferred first-line device therapy for benign prostatic hyperplasia. The FloStent System enables physicians to treat patients safely and efficiently, with minimal discomfort and reduced complications. The FloStent System is the first product Rivermark Medical plans to bring to market.

关于Rivermark Medical‍Rivermark Medical由一位执业泌尿科医生创立，旨在开发治疗良性前列腺增生的首选一线设备。FloStent系统使医生能够安全有效地治疗患者，同时减少不适和并发症。FloStent系统是Rivermark医疗计划推出的第一款产品。

For more information, please visit www.rivermarkmedical.com..

有关更多信息，请访问www.rivermarkmedical.com。。

SOURCE Rivermark Medical

来源Rivermark Medical